Literature DB >> 9105085

Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism.

N M Muñoz1, I Douglas, D Mayer, A Herrnreiter, X Zhu, A R Leff.   

Abstract

We studied the effects of the 5-lipoxygenase inhibition and sulfidopeptidyl leukotriene receptor antagonism on lumenal chemotaxis of eosinophils in 124 guinea pig tracheal explant preparations from 62 animals. Cell migration was assessed histologically and by differential cell count, and airway narrowing was measured by calibrated micrometry. Intralumenal instillation of the chemotaxin, formyl-met-leu-phe (FMLP) caused migration of 163,509 +/- 18,103 eosinophils/cm segment (eos/cm) versus 15,443 +/- 3,557 eos/cm for segments receiving vehicle only (p < 0.001). Coincubation of FMLP with zileuton, a selective inhibitor of 5-lipoxygenase, caused a concentration-related inhibition of eosinophil migration. At 10(-10) M zileuton, cell migration caused by FMLP was decreased by 57% and nearly complete reduction to 17,200 +/- 3,620 eos/cm resulted after 10(-6) M zileuton (p < 0.001 versus FMLP). Lumenal narrowing caused by FMLP (15.3 +/- 3.4%) was attenuated maximally to 1.15 +/- 2.51% after 10(-8) M zileuton (p < 0.02). In 36 preparations, concentration of leukotriene B4 (LTB4) was measured in treated tracheal perfusate. LTB4 secretion caused by FMLP was 6.4 +/- 0.48 pg/ml versus 3.32 +/- 0.89 pg/ml for buffer control at 5 min (p < 0.02) and was undetectable 120 min after activation with FMLP. Blockade of LTB4-receptor with the selective antagonist, LTB4 dimethyl amide, caused > 90% inhibition of eosinophil migration (p < 0.001). Comparable results were obtained with zafirlukast, an LTD4-receptor antagonist. Our data demonstrate that both LTB4 and LTD4 facilitate eosinophil migration from lamina propria to lumen caused by the chemotaxin, FMLP, and that LTB4-induced eosinophil migration is accompanied by initial lumenal secretion of LTB4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105085     DOI: 10.1164/ajrccm.155.4.9105085

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  11 in total

Review 1.  Leukotriene receptors.

Authors:  S E Dahlén
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways.

Authors:  A R Leff
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 3.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 4.  Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Authors:  Sabina Schmitt-Grohé; Stefan Zielen
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?

Authors:  M E Wechsler; R Pauwels; J M Drazen
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

6.  A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia.

Authors:  Shigeki Katoh; Nobuhiro Matsumoto; Kumiko Kawakita; Akira Tominaga; Paul W Kincade; Shigeru Matsukura
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 7.  Antileukotriene agents in asthma: the dart that kills the elephant?

Authors:  P M Renzi
Journal:  CMAJ       Date:  1999-01-26       Impact factor: 8.262

8.  Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma.

Authors:  Barbro Dahlén; Federico P Gómez; Alejandro Casas; Peter H Howarth; Sven-Erik Dahlén; Robert Rodriguez-Roisin
Journal:  Eur J Clin Pharmacol       Date:  2012-03-29       Impact factor: 2.953

9.  Churg-strauss syndrome in the pediatric age group.

Authors:  Yehia El-Gamal
Journal:  World Allergy Organ J       Date:  2008-02       Impact factor: 4.084

10.  Eosinophils in fungus-associated allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.